Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study ; volume:20 ; number:1 ; day:11 ; month:7 ; year:2018 ; pages:1-10 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (11.7.2018), 1-10, 12.2018
- Urheber
-
Pisaniello, Huai Leng
- Beteiligte Personen und Organisationen
-
Lester, Susan
Gonzalez-Chica, David
Stocks, Nigel
Longo, Marie
Sharplin, Greg R.
Dal Grande, Eleonora
Gill, Tiffany K.
Whittle, Samuel L.
Hill, Catherine L.
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1633-9
- URN
-
urn:nbn:de:101:1-2018091922432180475784
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pisaniello, Huai Leng
- Lester, Susan
- Gonzalez-Chica, David
- Stocks, Nigel
- Longo, Marie
- Sharplin, Greg R.
- Dal Grande, Eleonora
- Gill, Tiffany K.
- Whittle, Samuel L.
- Hill, Catherine L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout